Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

174
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
174
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

227
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
227
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

134
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
134
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

215
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
215
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

190
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
190
Pneumonia IV: Management01:28

Pneumonia IV: Management

312
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
312

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Central nervous system antituberculosis drug exposures in a rabbit model of tuberculous meningitis.

Antimicrobial agents and chemotherapy·2026
Same author

Integration of functional immunomonitoring assays with PET/CT scans in TB patients identifies on-treatment biomarkers.

bioRxiv : the preprint server for biology·2026
Same author

Rifamycin Structural Modifications Attenuate PXR Binding and CYP3A4 Induction.

Journal of medicinal chemistry·2026
Same author

Synthesis of 4-Aminoindole-Containing Cephalosporin Prodrugs and Their Biological Activity against <i>Mycobacterium tuberculosis</i>.

ACS infectious diseases·2026
Same author

Cytochrome P450-Mediated Metabolism of Antimycobacterial <i>N</i>α-Aroyl-<i>N</i>-aryl-phenylalanine Amides.

ACS infectious diseases·2026
Same author

Identification and Evaluation of Dibasic Piperidines as Cell Wall Inhibitors against <i>Mycobacterium tuberculosis</i>.

ACS infectious diseases·2026

Related Experiment Video

Updated: Jun 16, 2025

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

7.8K

Strategies for shortening tuberculosis therapy.

Véronique A Dartois1, Valerie Mizrahi2, Radojka M Savic3

  • 1Center for Discovery and Innovation, Hackensack Meridian School of Medicine, Nutley, NJ, USA. veronique.dartois@hmh-cdi.org.

Nature Medicine
|June 13, 2025
PubMed
Summary

Optimizing tuberculosis (TB) treatment duration requires patient stratification. Innovative strategies using host and pathogen factors can personalize therapy, reducing treatment length and overtreatment for better global TB control.

More Related Videos

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

1.8K
Visualization of the Charcoal Agar Resazurin Assay for Semi-quantitative, Medium-throughput Enumeration of Mycobacteria
09:57

Visualization of the Charcoal Agar Resazurin Assay for Semi-quantitative, Medium-throughput Enumeration of Mycobacteria

Published on: December 14, 2016

10.4K

Related Experiment Videos

Last Updated: Jun 16, 2025

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

7.8K
An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

1.8K
Visualization of the Charcoal Agar Resazurin Assay for Semi-quantitative, Medium-throughput Enumeration of Mycobacteria
09:57

Visualization of the Charcoal Agar Resazurin Assay for Semi-quantitative, Medium-throughput Enumeration of Mycobacteria

Published on: December 14, 2016

10.4K

Area of Science:

  • Infectious Diseases
  • Microbiology
  • Public Health

Background:

  • Current tuberculosis (TB) treatment often involves overtreatment due to a lack of patient-stratification methods.
  • Shortening TB treatment duration while maintaining efficacy is a major global health priority.

Purpose of the Study:

  • To review current knowledge on TB disease heterogeneity.
  • To propose approaches for optimizing TB treatment duration based on patient stratification.
  • To explore strategies for reducing TB treatment duration by integrating disease biology and pathology.

Main Methods:

  • Review of existing literature on TB disease heterogeneity.
  • Analysis of host and pathogen factors for patient stratification.
  • Exploration of therapeutic strategies for distinct patient groups.

Main Results:

  • Growing recognition of patient stratification as key to personalized TB treatment.
  • Insights into bacterial vulnerabilities in easy-to-treat and hard-to-treat TB.
  • Potential for reducing diagnostic uncertainties and optimizing treatment duration.

Conclusions:

  • Patient stratification is crucial for tailoring TB treatment duration.
  • Innovative strategies integrating disease biology can reduce treatment length.
  • Rethinking therapeutic approaches is essential for efficient global TB control.